Laboratory validation studies in Ki-67 digital image analysis of breast carcinoma: a pathway to routine quality assurance.


Journal

Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 26 08 2018
revised: 15 11 2018
accepted: 02 12 2018
pubmed: 10 3 2019
medline: 30 5 2019
entrez: 10 3 2019
Statut: ppublish

Résumé

Ki-67 proliferative index (PI) has prognostic and predictive value in invasive breast carcinoma (IBC), but clinical uptake has been hampered by suboptimal accuracy, reproducibility and standardisation. Published guidelines have addressed pre-analytical and analytical factors to improve Ki-67 PI utility; however, practicalities of ongoing monitoring of Ki-67 PI quality in IBC reporting have not been established. We aimed to evaluate the internal and external quality of our established digital Ki-67 PI IBC reporting practice at a tertiary institution. In the 5 years since initial validation work, we've completed a series of internal and external quality assurance (QA) projects: (1) an interobserver agreement study, (2) a two site interlaboratory agreement study, (3) determination of the error of our Ki-67 results, (4) an audit of the year-to-year Ki-67 values, (5) an audit of Ki-67 in neoadjuvant chemotherapy (NAC) treated cases, and (6) comparison of our Ki-67 datasets with similar published datasets. There was excellent concordance (intra-class correlation = 0.98) and good agreement [kappa (κ) = 0.76-0.96] between pathologists, excellent concordance [Pearson correlation (R) = 0.94] and very good agreement (κ = 0.80) between laboratories and excellent concordance (R = 0.92-0.95) and good agreement (κ = 0.67-1.0) over time for our Ki-67 results. No significant difference was observed in Ki-67 data from year-to-year. Expected associations with clinico-pathological prognosticators, pathological complete response following NAC and mitotic index were evident. The median Ki-67 values from the overall and NAC treated datasets were within the range reported in other studies, and our data could be separated into similarly proportioned 'high' and 'low' Ki-67 PI groups when dichotomised as per protocols in other studies. Collectively, our work provides evidence of adequate internal and external quality control for our digital Ki-67 PI IBC reporting protocols. Given the paucity of formal Ki-67 QA programs, our approach could be emulated, and results compared between laboratories as a framework for internal and external Ki-67 QA.

Identifiants

pubmed: 30850279
pii: S0031-3025(18)30395-7
doi: 10.1016/j.pathol.2018.12.416
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Ki-67 Antigen 0

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

246-252

Informations de copyright

Crown Copyright © 2019. Published by Elsevier B.V. All rights reserved.

Auteurs

Morgan Wang (M)

Breast Subspecialty Unit, PathWest Laboratory Medicine, QEII Medical Centre and Fiona Stanley Hospital Sites, Perth, WA, Australia.

Sally McLaren (S)

Breast Subspecialty Unit, PathWest Laboratory Medicine, QEII Medical Centre and Fiona Stanley Hospital Sites, Perth, WA, Australia.

Roopaa Jeyathevan (R)

Breast Subspecialty Unit, PathWest Laboratory Medicine, QEII Medical Centre and Fiona Stanley Hospital Sites, Perth, WA, Australia.

Benjamin Michael Allanson (BM)

Breast Subspecialty Unit, PathWest Laboratory Medicine, QEII Medical Centre and Fiona Stanley Hospital Sites, Perth, WA, Australia.

Amanda Ireland (A)

Breast Subspecialty Unit, PathWest Laboratory Medicine, QEII Medical Centre and Fiona Stanley Hospital Sites, Perth, WA, Australia.

Alexandra Kang (A)

Breast Subspecialty Unit, PathWest Laboratory Medicine, QEII Medical Centre and Fiona Stanley Hospital Sites, Perth, WA, Australia.

Katie Meehan (K)

Breast Subspecialty Unit, PathWest Laboratory Medicine, QEII Medical Centre and Fiona Stanley Hospital Sites, Perth, WA, Australia; School of Biomedical Science, UWA, Crawley, WA, Australia.

Carla Thomas (C)

Breast Subspecialty Unit, PathWest Laboratory Medicine, QEII Medical Centre and Fiona Stanley Hospital Sites, Perth, WA, Australia; School of Biomedical Science, UWA, Crawley, WA, Australia.

Cleo Robinson (C)

Breast Subspecialty Unit, PathWest Laboratory Medicine, QEII Medical Centre and Fiona Stanley Hospital Sites, Perth, WA, Australia; School of Biomedical Science, UWA, Crawley, WA, Australia.

Marais Combrinck (M)

Breast Subspecialty Unit, PathWest Laboratory Medicine, QEII Medical Centre and Fiona Stanley Hospital Sites, Perth, WA, Australia; Division of Pathology and Laboratory Medicine, Medical School, UWA, Crawley, WA, Australia.

Jennet Harvey (J)

Breast Subspecialty Unit, PathWest Laboratory Medicine, QEII Medical Centre and Fiona Stanley Hospital Sites, Perth, WA, Australia; School of Biomedical Science, UWA, Crawley, WA, Australia; Division of Pathology and Laboratory Medicine, Medical School, UWA, Crawley, WA, Australia.

Greg Sterrett (G)

Breast Subspecialty Unit, PathWest Laboratory Medicine, QEII Medical Centre and Fiona Stanley Hospital Sites, Perth, WA, Australia; Division of Pathology and Laboratory Medicine, Medical School, UWA, Crawley, WA, Australia.

Benjamin Dessauvagie (B)

Breast Subspecialty Unit, PathWest Laboratory Medicine, QEII Medical Centre and Fiona Stanley Hospital Sites, Perth, WA, Australia; School of Biomedical Science, UWA, Crawley, WA, Australia; Division of Pathology and Laboratory Medicine, Medical School, UWA, Crawley, WA, Australia. Electronic address: ben.dessauvagie@health.wa.gov.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH